Cargando…
Lipophilic statins inhibit Zika virus production in Vero cells
Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family. ZIKV infection has been associated with neurological complications such as microcephaly in newborns and Guillain-Barré syndrome in adults; thus, therapeutic agents are urgently needed. Statins are clinically approved for loweri...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685969/ https://www.ncbi.nlm.nih.gov/pubmed/31391514 http://dx.doi.org/10.1038/s41598-019-47956-1 |
_version_ | 1783442469675859968 |
---|---|
author | Españo, Erica Nam, Jeong-Hyun Song, Eun-Jung Song, Daesub Lee, Chong-Kil Kim, Jeong-Ki |
author_facet | Españo, Erica Nam, Jeong-Hyun Song, Eun-Jung Song, Daesub Lee, Chong-Kil Kim, Jeong-Ki |
author_sort | Españo, Erica |
collection | PubMed |
description | Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family. ZIKV infection has been associated with neurological complications such as microcephaly in newborns and Guillain-Barré syndrome in adults; thus, therapeutic agents are urgently needed. Statins are clinically approved for lowering cholesterol levels to prevent cardiovascular disease but have shown potential as antiviral drugs. In this study, we explored the possibility of utilizing statins as anti-ZIKV drugs. We found that, generally, lipophilic statins (atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, and simvastatin) could reduce ZIKV production in vitro and result in smaller foci of infection. Time-of-drug-addition assay revealed that early treatment with statins is more beneficial than late treatment; however, statins could not completely inhibit the entry stage of ZIKV infection. Furthermore, individual lipophilic statins differed in anti-ZIKV capacity, with fluvastatin being the most efficient at low concentrations. Taken together, this study shows that statins or their derivatives have the potential to be used as anti-ZIKV therapeutic agents. |
format | Online Article Text |
id | pubmed-6685969 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-66859692019-08-12 Lipophilic statins inhibit Zika virus production in Vero cells Españo, Erica Nam, Jeong-Hyun Song, Eun-Jung Song, Daesub Lee, Chong-Kil Kim, Jeong-Ki Sci Rep Article Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family. ZIKV infection has been associated with neurological complications such as microcephaly in newborns and Guillain-Barré syndrome in adults; thus, therapeutic agents are urgently needed. Statins are clinically approved for lowering cholesterol levels to prevent cardiovascular disease but have shown potential as antiviral drugs. In this study, we explored the possibility of utilizing statins as anti-ZIKV drugs. We found that, generally, lipophilic statins (atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, and simvastatin) could reduce ZIKV production in vitro and result in smaller foci of infection. Time-of-drug-addition assay revealed that early treatment with statins is more beneficial than late treatment; however, statins could not completely inhibit the entry stage of ZIKV infection. Furthermore, individual lipophilic statins differed in anti-ZIKV capacity, with fluvastatin being the most efficient at low concentrations. Taken together, this study shows that statins or their derivatives have the potential to be used as anti-ZIKV therapeutic agents. Nature Publishing Group UK 2019-08-07 /pmc/articles/PMC6685969/ /pubmed/31391514 http://dx.doi.org/10.1038/s41598-019-47956-1 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Españo, Erica Nam, Jeong-Hyun Song, Eun-Jung Song, Daesub Lee, Chong-Kil Kim, Jeong-Ki Lipophilic statins inhibit Zika virus production in Vero cells |
title | Lipophilic statins inhibit Zika virus production in Vero cells |
title_full | Lipophilic statins inhibit Zika virus production in Vero cells |
title_fullStr | Lipophilic statins inhibit Zika virus production in Vero cells |
title_full_unstemmed | Lipophilic statins inhibit Zika virus production in Vero cells |
title_short | Lipophilic statins inhibit Zika virus production in Vero cells |
title_sort | lipophilic statins inhibit zika virus production in vero cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685969/ https://www.ncbi.nlm.nih.gov/pubmed/31391514 http://dx.doi.org/10.1038/s41598-019-47956-1 |
work_keys_str_mv | AT espanoerica lipophilicstatinsinhibitzikavirusproductioninverocells AT namjeonghyun lipophilicstatinsinhibitzikavirusproductioninverocells AT songeunjung lipophilicstatinsinhibitzikavirusproductioninverocells AT songdaesub lipophilicstatinsinhibitzikavirusproductioninverocells AT leechongkil lipophilicstatinsinhibitzikavirusproductioninverocells AT kimjeongki lipophilicstatinsinhibitzikavirusproductioninverocells |